The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | HMA with or without venetoclax in treatment-naïve MDS with excess blasts: a retrospective analysis
Alex Bataller, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses findings from a retrospective analysis comparing treatment with a hypomethylating agent (HMA) with and without venetoclax in treatment-naïve myelodysplastic syndromes (MDS) with excess blasts. Dr Bataller highlights a higher overall response rate (ORR) with HMA-venetoclax and discusses potential subgroups, including patients with ASXL1 mutations or higher blast counts, who may benefit most from the addition of venetoclax. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
